Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Colorectal Neoplasms 2Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

Octreotide 5Everolimus 5pasireotide 3lanreotide 2Bevacizumab 2surufatinib 1pembrolizumab 1ganitumab 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1azaspirane 1arginyllysine 1TKM-080301 1Sunitinib 1Rose Bengal 1Random Allocation 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1CX 3543 1Biological Therapy 1Biological Factors 12-Methoxyestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoid Tumor × cixutumumab × Clear all
NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡